Network Point-of-Care Glucose Testing Market Insights – Growth, Demand & Forecast 2022-2032

Network Point-of-Care Glucose Testing Market Outlook (2022 to 2032)

The global Network Point-of-Care Glucose Testing Market was valued at around USD 1.5 billion in 2021.

With a projected CAGR of 4.8% for the next ten years, the market is likely to reach a valuation of nearly USD 2.5 billion by the end of 2032. The Global absolute dollar opportunity growth in network point-of-care glucose testing is projected to be at USD 923.3 million by 2032.

Attributes	Details
Network Point-of-Care Glucose Testing Market Size (2021)	USD 1.5 billion
Network Point-of-Care Glucose Testing Market Size (2022)	USD 1.6 billion
Projected Market Value (2032)	USD 2.5 billion
Global Market Growth Rate (2022 to 2032)	4.8% CAGR
Key Companies Profiled	F. Hoffmann-La Roche Ltd.; Danaher.; Abbott; Nipro; PlatInium Equity Advisors, LLC; Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics

Sales Analysis of Network Point-of-care Glucose Testing Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Network point-of-care glucose testing is a growing testing method that does not require testing in the laboratory but is instead performed near or at the site of the patient to monitor the glucose levels. This ensures minimal risk of infection and provides information within a few seconds.

Future Market Insights reveals that revenue from Accu-Chek Inform II dominated the segment of product type. Revenue from Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. It is projected to achieve a growth rate of 4.9% during the forecasted period of 2022 to 2032.

On the other hand, North America dominated the market for network-point-of-care glucose testing. It achieved a growth rate of 4.8% from 2017 to 2021 and is projected to witness revenue growth of 4.9% CAGR over the forecasted period.

How the management of patient data and remote patient monitoring is driving the market for network-point-of-care glucose testing?

Network Point-of-care glucose testing is significantly gaining traction for the diagnosis of diabetes as well as for analyzing patients’ health conditions. It has come as an efficient tool for preventing delays in treatment and providing results in less time. Moreover, the demand for remote patient monitoring systems and the need for data-based patient results are driving the market for network point-of-glucose testing.

As the number of diabetes patients is surging, there is an increasing demand to incorporate the patient data and perform proper management of the data to derive insightful information and develop an advanced method for data transfer techniques.

How growing incidence of diabetes among older adults is influencing the growth of the network-point-of-care glucose testing market?

The growing incidence of diabetes necessitates glucose testing among individuals. According to WHO data, 422 million people globally are suffering from diabetes, the majority of whom are living in underdeveloped countries.

Therefore, the treatment of glucose testing becomes vital for these nations as they remain undiagnosed and are at risk of developing diseases associated with diabetes such as blindness, kidney failure, stroke, and heart attack.

Based on a WHO report in 2019, diabetes contributed to the ninth leading cause of death with an estimation of 1.5 million deaths. According to Diabetes Federation data published in 2021, almost 1 in 2 diabetes patients were undiagnosed, and in Asia-Pacific, the proportion was estimated to be 55%, largely contributed by India, China, and Indonesia.

Therefore, it becomes essential to expand the coverage of network point-of-care glucose testing methods in low and middle-income countries as well as developed countries.

Regional Insights

How is the market for Network point-of-care glucose testing in North America expected to perform in forthcoming years?

North America is the largest user of network point-of-care testing methods. Revenue through Network point-of-care glucose testing grew at a CAGR of 4.8% from 2017 to 2021. North America is expected to dominate the market with a 4.9% CAGR from 2022 to 2032. Prominent key players such as Abbott, Nova Medical, and prodigy Diabetes Care, LLC are aiding the regional market growth. Moreover, several initiatives by the government and not-for-profit organizations to increase awareness about the adoption of advanced glucose meters are driving growth in North America.

Country-wise Insights

The USA Network point-of-care glucose testing Market Analysis

The network point-of-care glucose testing market in the USA was valued at USD 735 million by 2032. Revenue through the market grew at 4.6% CAGR from 2017 to 2021. The projected growth rate in the network point-of-care glucose testing market is 4.9% over the forecasted period. According to the data from American Diabetes Association, almost 37.3 million Americans, or 11.3% of the population had diabetes in 2019.

Out of which 8.5 million were undiagnosed and 244,000 children and adolescents in the USA were suffering from diabetes. This necessitates the need for conducting point-of-care glucose testing among individuals and ensuring early recovery from chronic disease.

Key companies like Abbott had maintained their presence in the USA market by providing FreeStyl e Libre 2 integrated continuous glucose monitoring system which is used by the most number of Americans to track health statistics in a mobile app. The absolute dollar opportunity growth in the network point-of-care glucose testing market in the USA is USD 276.2 million by 2032.

The United Kingdom Network point-of-care glucose testing Market Analysis

The network point-of-care glucose testing market in the United Kingdom is projected to reach a valuation of USD 119 million by 2032. Growing at a CAGR of 5.8%, the market is expected to register an absolute dollar opportunity of USD 50.6 million from 2022 to 2032.

Japan Network point-of-care glucose testing Market Analysis

The market in Japan is expected to gross an absolute dollar opportunity of USD 36 million during the forecast period. Growing at a CAGR of 4.5%, the market is likely to reach a valuation of USD 101 million by 2032.

South Korea Network point-of-care glucose testing Market Analysis

In South Korea, the market is projected to reach a valuation of USD 59 million by 2032. Growing at a CAGR of 4.9%, the market from 2022 to 2032 is expected to gross an absolute dollar opportunity of USD 23 million.

Category-wise Insights

Why is the demand for Accu-Chek Inform II rising in Network Point-of-care glucose testing market?

Accu-Chek Inform II is widely used as a point-of-care glucose testing monitor. Revenue through Accu-Chek Inform II grew at a CAGR of 4.5% from 2017 to 2021. The anticipated growth rate of Accu-Chek Inform II is 4.9% during the forecasted period of 2022 to 2032.

The rise in the use of Accu-Chek Inform II is attributed to its automatic real-time wireless features which enable proper transmission of patient data between the medical staff and the laboratories. The system also offers unique features such as unique identification of patients to avoid inaccuracy.

How is the market for network point-of-care glucose testing shaping up in Asia-Pacific?

Due to the prevalence of diabetes in Asia, the network point-of-care glucose testing market is expected to witness growth in the forecasted period. Almost 90 million adults are suffering from diabetes in the IDF South-East Asia region and is estimated to witness a spike in diabetes patients to 152 million by 2045. Countries in the Asia-Pacific have made efforts to employ point-of-care glucose testing methods to reduce the occurrence of diabetes.

For instance, in China, the government incentivized hospitals to employ diabetes management systems. Hospitals in Tianjin have administered blood glucose information systems to improvise blood glucose monitoring, treatment, and management.

Competitive Landscape

Companies involved in network point-of-care glucose testing are solely aiming at increasing diabetes awareness and producing advanced point-of-care glucose testing devices. The key companies operating in the network point-of-care glucose testing market include F.

Hoffmann-La Roche Ltd. Danaher, Abbott, Nipro, Platinum Equity Advisors, LLC (Lifescan, Inc.), Nova Biomedical, ACON Laboratories, Trividia Health, Inc., Prodigy Diabetes Care, LLC, Bayer AG/Ascensia Diabetes Care Holdings AG, EKF Diagnostics and others.

Some of the recent developments by key providers of Network Point-of-Care Glucose Testing are as follows:

• In January 2022, to manage blood glucose solutions, Roche announced the release of the Cobas pulse system. It is meant to be the first diagnostic tool available at the point of care and give users a way to communicate with the creators of digital health software and applications. As a result, clinical insights will be made simpler and patient care will be improved.
• In October 2021, EKF diagnostics introduced a handheld analyzer STAT-Site WB. It is primarily used for the determination of β-ketone and glucose measurements from the whole blood in seconds. It uses two different test strips to send results in 10 seconds for β-ketones and 5 seconds for glucose.
• In May 2020, EKF Diagnostics Collaborated with Tosoh Europe N.V. for the distribution of a Quo-Test HbA1c point-of-care (POC) analyzer in the Middle East and Africa. The aim of the collaboration is to expand the need for those who are at a greater risk of suffering from diabetes.
• In September 2019, an On Call Express Voice was made available in the USA market by ACON laboratories. This feature complements the family of blood glucose meters produced by ACON laboratories. To assist the user and get the most out of the audible blood glucose meter, it includes navigation and an audio feature.

Similarly, recent developments related to companies operating in the network point-of-care glucose testing market have been tracked by the team at Future Market Insights, which is available in the full report.

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
• 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type
  • 5.1. i-STAT
  • 5.2. Accu-Chek Inform II
  • 5.3. StatStrip
  • 5.4. HemoCue
  • 5.5. CareSens Expert Plus
  • 5.6. BAROzen H Expert Plus
• 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
  • 6.1. North America
  • 6.2. Latin America
  • 6.3. Europe
  • 6.4. Asia Pacific
  • 6.5. Middle East and Africa
• 7. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 8. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 9. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 10. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 11. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
• 12. Key Countries Market Analysis
• 13. Market Structure Analysis
• 14. Competition Analysis
  • 14.1. F. Hoffmann-La Roche Ltd.
  • 14.2. Danaher
  • 14.3. Abbott
  • 14.4. Nipro
  • 14.5. PlatInium Equity Advisors, LLC
  • 14.6. Nova Biomedical
  • 14.7. ACON Laboratories
  • 14.8. Trividia Health, Inc.
  • 14.9. Prodigy Diabetes Care, LLC
  • 14.10. Bayer AG/Ascensia Diabetes Care Holdings AG
  • 14.11. EKF Diagnostics
• 15. Assumptions & Acronyms Used
• 16. Research Methodology